Log in to search using one of your social media accounts:

 

Noxopharm initiates Phase Ib trial of NOX66 for prostate cancer

Australia-based Noxopharm has initiated a Phase Ib clinical trial of NOX66 in metastatic castrate-resistant prostate cancer patients who do not have remaining standard therapeutic options.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

Authors: Huang F, Zhao H, Du Z, Jiang H Abstract Previous studies have reported that miR-615 exerts a tumor suppressor in some tumors, such as esophageal squamous cellcarcinoma and non-small cell lung cancer. However, the role of miR-615 in prostate cancer cells has not been defined. Here, we found that miR-615 was downregulated in prostate cancer tissues and cell lines. And overexpression of miR-615 in PC-3 cells significantly inhibited cellular proliferation, migration and invasion. Moreover, overexpression of miR-615 delayed tumor growth in vivo. In term of mechanism, we found that Cyclin D2 is a target gene of ...
Source: Oncology Research - Category: Cancer & Oncology Tags: Oncol Res Source Type: research
Authors: Kang S, Zhao Y, Wang L, Liu J, Chen X, Liu X, Shi Z, Gao W, Cao F Abstract Numerous previous studies reported the association of Vitamin D receptor gene Taq Ipolymorphism with prostate cancer risk, however these results were controversial. In order to provide a relatively comprehensive description of this relationship, we conducted this meta-analysis by searching PubMed, Embase, and China National Knowledge Infrastructure. Finally, 36 studies with 8,423 cases and 8,887 controls were included. Taq I polymorphism was found to marginally increase the prostate cancer risk in recessive genetic model (tt/Tt vs. ...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
CONCLUSIONS: The risk of cancer is low in Korean patients with AAV. PMID: 29465366 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
Publication date: Available online 18 February 2018 Source:Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms Author(s): Elena Magnani, Filippo Macchi, Monica Mancini, Vanessa Lomazzi, Sara Cogliati, Christian Pistore, Martina Mandruzzato, Anne-Catherine Dock-Bregeon, Ian Marc Bonapace Non-coding RNAs (ncRNAs) transcribed from the promoter and the downstream region can affect the expression of the corresponding coding genes. It has been shown that sense-directed ncRNAs arising from the promoter region of the E-cadherin gene (CDH1) mediate its repression. Here, we show that an antisense-directed ncRNA (paRCDH...
Source: Biochimica et Biophysica Acta (BBA) Gene Regulatory Mechanisms - Category: Genetics & Stem Cells Source Type: research
Hassan et al assessed the risk of locally aggressive behavior of pure GS6 prostate cancer in RP specimens. They found that it was not rare for pure GS6 PCa to show extraprostatic extension and yet not lymph node metastasis.
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Tags: Adult Urology Source Type: research
Enzalutamide may have a role in prostate cancer therapy, but randomized trials are needed, says Dr Chodak.Medscape Urology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Urology Commentary Source Type: news
Condition:   Prostate Cancer Recurrent Intervention:   Diagnostic Test: 68Ga-HBED-CC-PSMA PET / CT Sponsor:   Institut Cancerologie de l'Ouest Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Prostate Cancer Recurrent Intervention:   Drug: Ga-68 P16-093 PET/CT scan Sponsors:   Five Eleven Pharma, Inc.;   Indiana University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Cancer of Prostate;   Insomnia Intervention:   Behavioral: 12-week aerobic exercise and cognitive-behavioral therapy Sponsor:   Danish Cancer Society Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Prostate Cancer Recurrent Intervention:   Diagnostic Test: 68Ga-HBED-CC-PSMA PET / CT Sponsor:   Institut Cancerologie de l'Ouest Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Australia Health | Cancer | Cancer & Oncology | Clinical Trials | Pharmaceuticals | Prostate Cancer